<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>ahi evran med j</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Ahi Evran Medical Journal</journal-title>
            </journal-title-group>
                                        <issn pub-type="epub">2619-9203</issn>
                                                                                            <publisher>
                    <publisher-name>Kirsehir Ahi Evran University</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id pub-id-type="doi">10.46332/aemj.1637016</article-id>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Clinical Chemistry</subject>
                                                            <subject>Clinical Oncology</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Klinik Kimya</subject>
                                                            <subject>Klinik Onkoloji</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <article-title>İnsan Kronik Myeloid Lösemi Hücreleri Üzerine Florlu Shiff Bazı Ligandları ile Bunların Bakır ve Paladyum Komplekslerinin Antikanser Aktiviteleri</article-title>
                                                                                                                                                                                                <trans-title-group xml:lang="en">
                                    <trans-title>Anticancer Activities of Fluorinated Shiff Base Ligands and Their Copper and Palladium Complexes on Human Chronic Myeloid Leukemia Cells</trans-title>
                                </trans-title-group>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-5000-0998</contrib-id>
                                                                <name>
                                    <surname>Süzergöz</surname>
                                    <given-names>Faruk</given-names>
                                </name>
                                                                    <aff>HARRAN UNIVERSITY</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0009-0002-1655-836X</contrib-id>
                                                                <name>
                                    <surname>Variş</surname>
                                    <given-names>Yusuf</given-names>
                                </name>
                                                                    <aff>HARRAN ÜNİVERSİTESİ</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-6058-9414</contrib-id>
                                                                <name>
                                    <surname>Okşak</surname>
                                    <given-names>Nilgün</given-names>
                                </name>
                                                                    <aff>HARRAN ÜNİVERSİTESİ, SAĞLIK BİLİMLERİ FAKÜLTESİ</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-5455-0353</contrib-id>
                                                                <name>
                                    <surname>Boyraz</surname>
                                    <given-names>Mustafa Ünal</given-names>
                                </name>
                                                                    <aff>HARRAN UNIVERSITY</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-8849-4153</contrib-id>
                                                                <name>
                                    <surname>Shekhany</surname>
                                    <given-names>Bestoon</given-names>
                                </name>
                                                                    <aff>Erbil Polytechnic University</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0001-5704-7801</contrib-id>
                                                                <name>
                                    <surname>Kasım</surname>
                                    <given-names>Veli</given-names>
                                </name>
                                                                    <aff>HARRAN ÜNİVERSİTESİ</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20260429">
                    <day>04</day>
                    <month>29</month>
                    <year>2026</year>
                </pub-date>
                                        <volume>10</volume>
                                        <issue>1</issue>
                                        <fpage>79</fpage>
                                        <lpage>87</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20250210">
                        <day>02</day>
                        <month>10</month>
                        <year>2025</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20260102">
                        <day>01</day>
                        <month>02</month>
                        <year>2026</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 2017, Ahi Evran Medical Journal</copyright-statement>
                    <copyright-year>2017</copyright-year>
                    <copyright-holder>Ahi Evran Medical Journal</copyright-holder>
                </permissions>
            
                                                                                                <abstract><p>Amaç: Kanser tedavisinde kemoterapatiklere bağlı yan etkilerin ortaya çıkması, ilaç direnci gelişimi en önemli sorunların başında gelmektedir. Bu güçlüklerin üstesinden gelebilmek için yeni antikanser ajanları araştırmalarına olan ihtiyaç artmaktadır. Son yıllarda Schiff bazlarının antikanser aktiviteye sahip olduğuna dair veriler dikkat çekmektedir. Bu bileşiklerin kanser hücrelerinde apoptozuindükleyerek hücre ölümüne yol açtığı ve DNA ve RNA sentezini durdurarak hücre çoğalmasını engellediği bildirilmektedir.Çalışmada, florlu Schiff bazları ile bunların bakır ve paladyum komplekslerinin insan kronik myeloid lösemi hücreleri üzerindeki sitotoksik etkileri araştırılmıştır.Araçlar ve Yöntem: K562 lösemi hücrelerinde florlu Schiff bazlarından o-florofenil-3,5-di-tert-butilsalisilaldimin [o-FPh-3,5-DTBS] ve p-florofenil-3,5-di-tert-butilsalisilaldimin [o-FPh-3,5-DTBS]) bileşiği ve bu bileşiklerin bakır ile paladyum komplekslerinin sitotoksik etkileri kolorimetrik olarak MTT yöntemiyle belirlendi. Bu amaçla sentezlenen altı bileşiğin 1-1000 μM aralığındaki logaritmik dozları kullanıldı. K562 hücrelerinin bileşiklerle 72 saat inkübasyondan sonra elde edilen optik dansite (OD) verilerinden yararlanılarak her bileşiğe ait IC50 değeri hesaplandı.Bulgular: K562 hücrelerde o-FPh-3,5-DTBS bileşiğinin, p-FPh-3,5-DTBS bileşiğine kıyasla daha yüksek sitotoksik etkiye sahip olduğu tespit edilmiştir. Aynı zamanda bu bileşiklerin bakır kompleksleri, paladyum komplekslerine göre daha güçlü sitotoksik etki göstermiştir.Sonuç: Sitotoksik etkiye sahip bu bileşikler ile yapılacak ileri düzeydeki çalışmaların faydalı olacağını düşünmektedir.</p></abstract>
                                                                                                                                    <trans-abstract xml:lang="en">
                            <p>Purpose: The emergence of side effects due to chemotherapeutics in cancer treatment and the development of drug resistance are among the most important problems. In order to overcome these difficulties, the need for new anticancer agent research increases. In recent years, data indicating that Schiff bases have anticancer activity has attracted attention. It is reported that these compoundscause cell death by inducing apoptosis in cancer cells and prevent cell proliferation by stopping DNA and RNA synthesis. In the study, the cytotoxic effects of fluorinated Schiff bases and their copper and palladium complexes on human chronic myeloid leukemia cells were investigated.Materials and Methods: Cytotoxic effects of fluorine-containing Schiff bases (o-fluorophenyl-3,5-di-tert-butylsalicylaldimine [oFPh-3,5-DTBS] and p-fluorophenyl-3,5-di-tert-butylsalicylaldimine [o-FPh-3,5-DTBS]) and their copper and palladium complexes were determined colorimetrically by the MTT method. For this purpose, logarithmic doses of each of the six compounds synthesizedin the range of 1-1000 μM were used. IC50values of each compound were calculated using the OD data obtained after 72 hours of incubation of K562 cells with the compounds.Results: The cytotoxic effect of o-FPh-3,5-DTBS on K562 cells was determined to be higher compared to p-FPh-3,5-DTBS. At the same time, copper complexes of Schiff bases showed stronger cytotoxic effects on K562 cells, while this effect was found to be weak in palladium complexes.Conclusion: We believe that further research on compounds with high cytotoxic effects may yield useful results.</p></trans-abstract>
                                                            
            
                                                            <kwd-group>
                                                    <kwd>K562 hücre</kwd>
                                                    <kwd>  MTT yöntemi</kwd>
                                                    <kwd>  schiff baz</kwd>
                                                    <kwd>  Sitotoksisite</kwd>
                                            </kwd-group>
                                                        
                                                                            <kwd-group xml:lang="en">
                                                    <kwd>Cytotoxicity</kwd>
                                                    <kwd>  K562 Cell</kwd>
                                                    <kwd>  MTT method</kwd>
                                                    <kwd>  schiff base</kwd>
                                            </kwd-group>
                                                                                                        <funding-group specific-use="FundRef">
                    <award-group>
                                                    <funding-source>
                                <named-content content-type="funder_name">Bu çalışma Harran üniversitesi HÜBAP (Proje No: 13105) birimi tarafından desteklenmiştir.</named-content>
                            </funding-source>
                                                                            <award-id>13105</award-id>
                                            </award-group>
                </funding-group>
                                </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">1. American Cancer Society. Cancer Facts &amp; Figures. 2024. Accessed June 26, 2024. Erişim Linki:
https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html. Erişim Tarihi:11.12.2024.</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">2. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99(11): 2191‐2212. doi:10.1002/ajh.27443.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">3. Bourne G, Bhatia R, Jamy O. Treatment-Free Remission in Chronic Myeloid Leukemia. J Clin Med. 2024;13(9): 2567-78. doi:10.3390/jcm13092567.</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">4. Shah NP, Bhatia R, Altman JK et al. (). Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2024; 22(1): 43-69. doi:10.6004/jnccn.2024.0007.</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">5. Kantarjian H, Paul S, Thakkar J, Jabbour E. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol. 2022;9(11): e854-e861.</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">6. Prakash A, Adhikari D. Application of Schiff bases and their metal complexes-A Review. Int. J. ChemTech Res. 2011; 3(4): 1891-1896.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">7. Savalia RV, Patel AP, Trivedi PT et al. Rapid and Economic Synthesis of Schiff Base of Salicylaldehyde by Microwave Irradiation. Res. J. Chem. Sci. 2013; 3: 97–99.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">8. Serin S, Gök Y. Hidroksi Schiff Bazı Metal Komplekslerinin Tekstil Boyamacılığında Kullanabilirliğinin İncelenmesi. T. Kimya D.C. 1988; 12(3): 325- 331.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">9. Zeishen W, Zigi G, Zhenhuan Y. Synthesis, Characterization And Anticanser Activity Of L–Alanin Schiff Base Complexes Of Cooper (II), Zinc(II), An Cobalt (II) . Synth. React. Inorg. Met. Org. Chem. 1990; 20(3): 335–344.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">10. Dığrak M, Selvi S, Ahmedov MA, Bağcı E. 1,5-dien3ol’lerin Antimikrobiyal Etkilerinin İncelenmesi. XII. Ulusal Kimya Kongresi, Y.Y Üniversitesi Fen-Edebiyat Fakültesi Kimya Bölümü, Kongre Özetler Kitabı, Van, 1997; 677s.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">11. Kumar R, Singh AA, Kumar U et al. Recent advances in synthesis of heterocyclic Schiff base transition metal complexes and their antimicrobial activities especially antibacterial and antifungal. J. Mol. Struct. 2023; 1294: 136346.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">12. Kaushik S, Paliwal SK, Iyer MR, Patil VM. Promising Schiff bases in antiviral drug design and discovery. Med Chem Res. 2023;32(6): 1063-1076. doi: 10.1007/s00044-023-03068-0.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">13. Oveisi Keikha A, Shahraki S, Mansouri-Torshizi H, Dehghanian E, Heidari Majd M. Au (III) complexes of symmetrical tetradentate Schiff base ligands: Synthesis, characterization, anticancer/antioxidant potency, in silico prediction, and catalase binding properties Appl. Organomet. Chem. 2023;37(7):e7139. doi:10.1002/aoc.7139.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">14. Keikha AO, Mansouri-Torshizi H, Shahraki S, Dehghanian E. Zn (II) and Pd (II) complexes derived from novel benzohydrazide-based Schiff base ligand as multi-target agents J. Mol. Liq. 2023;391(Part A):123272. doi:10.1016/j.molliq.2023.123272.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">15. Shahraki S. Schiff base compounds as artificial metalloenzymes. Colloids Surf B Biointerfaces. 2022; 218:112727. doi: 10.1016/j.colsurfb.2022.112727.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">16. Damena T, Zeleke D, Desalegn T, Demissie TB, Eswaramoorthy R. Synthesis, characterization, and biological activities of novel vanadium (IV) and cobalt (II) complexes. ACS Omega. 2022;7:4389-4404.</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">17. Shahraki S, Vaziri E, Saboury AA, Fan K. Biomedical potential of nanozymes: Harnessing redox enzyme mimicry for theranostic applications. Coord. Chem. Rev. 2024;517:215937. doi:10.1016/j.ccr.2024.215937.</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">18. Barani O, Shahraki S, Nezami ZS, Delarami HS, E. Sanchooli Unveiling the molecular association of novel benzohydrazidesubstituted Schiff base complexes with human serum albümin. Inorg. Chem. Commun. 2024;162:112200.</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">19. Shahraki K, Shahraki S, Nezami ZS, Delarami HS. New acetohydrazide-based Schiff base complexes with the ability to enhance catalase activity. Inorg. Chem. Commun. 2024;163:112318. doi:.1016/j.inoche.2024.112200.</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">20. Shahraki S, Majd MH, Heydari A. Novel tetradentate Schiff base zinc (II) complex as a potential antioxidant and cancer chemotherapeutic agent: Insights from the photophysical and computational approach. J. Mol. Struct. 2019;1177:536-544.</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">21. Matela G. Schiff Bases and Complexes: A Review on Anti-Cancer Activity. Anticancer Agents Med Chem. 2020;20(16):1908-1917. doi: 10.2174/1871520620666200507091207.</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">22. Yılmaz ZK, Özdemir Ö, Aslim B, Suludere Z, Şahin E. A new bio-active asymmetric-Schiff base: synthesis and evaluation of calf thymus DNA interaction, topoisomerase IIα inhibition, in vitro antiproliferative activity, SEM analysis and molecular docking studies. J Biomol Struct Dyn. 2023;41(7):2804-2822. doi: 10.1080/07391102. 2022.2039297.</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">23. Alvero AB, Chen W, Sartorelli AC et al. Triapine (3-amino- 2-carboxaldehyde thiosemicarbazone) Induces Apoptosis in Ovarian Cancer Cells. J. Soc. Gynecol. Investig. 2006;13:145–152. doi: 10.1016/j.jsgi.2005.11.004.</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">24. Niu ZX, Hu J, Sun JF, Wang YT. Fluorine in the pharmaceutical industry: Synthetic approaches and application of clinically approved fluorine-enriched anti-infectious medications. Eur J Med Chem. 2024;271:116446. doi: 10.1016/j.ejmech.2024.116446.</mixed-citation>
                    </ref>
                                    <ref id="ref25">
                        <label>25</label>
                        <mixed-citation publication-type="journal">25. Zakaria N, Kandile NG, Mohamed MI, Zaky HT, Mohamed HM. Superior remedy colon cancer HCT-116 cells via new chitosan Schiff base nanocomposites: Synthesis and characterization. Int J Biol Macromol. 2024; 281(Pt 1): 135916. doi:10.1016/j.ijbiomac.2024.135916.</mixed-citation>
                    </ref>
                                    <ref id="ref26">
                        <label>26</label>
                        <mixed-citation publication-type="journal">26. Podolski-Renić A, Čipak Gašparović A, Valente A et al. Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer. Eur J Med Chem. 2024; 270:116363. doi: 10.1016/j.ejmech. 2024.116363.</mixed-citation>
                    </ref>
                                    <ref id="ref27">
                        <label>27</label>
                        <mixed-citation publication-type="journal">27. Chen S, Liu X, Ge X et al., Lysosome-targeted iridium (III) compounds with pyridine-triphenylamine Schiff base ligands: syntheses, antitumor applications and mechanisms. Inorg. Chem. Front. 2020;7:91–100. doi:10.1039/C9QI01161G.</mixed-citation>
                    </ref>
                                    <ref id="ref28">
                        <label>28</label>
                        <mixed-citation publication-type="journal">28. Nemat A, Khan IN, Kalsoom S. et al., Synthesis, anticancer evaluation and molecular docking studies of methotrexate&#039;s novel Schiff base derivatives against malignant glioma cell lines. J. Biomol. Struct. Dyn. 2022;40:2865–2877. doi:10.1080/07391102.2020.1844053.</mixed-citation>
                    </ref>
                                    <ref id="ref29">
                        <label>29</label>
                        <mixed-citation publication-type="journal">29. Osowole, AA, Akpan EJ,. Synthesis, Spectroscopic Characterisation, İn-Vitro Anticancer And Antimicrobial and Properties of Some Metal(II) Complexes of 3-{4,6-dimethoxypyrimidinyl) imino methyl}naphthalen-2-ol. Eur. J. Appl. Sci. 2012; 4(1):14-20. doi:10.9734/IRJPAC/2012/1540.</mixed-citation>
                    </ref>
                                    <ref id="ref30">
                        <label>30</label>
                        <mixed-citation publication-type="journal">30. Oveisi Keikha A, Shahraki S, Dehghanian E, Mansouri-Torshizi H. Effect of central metal ion on some pharmacological properties of new Schiff base complexes. Anticancer, antioxidant, kinetic/thermodynamic and computational studies. Spectrochim. Acta A Mol. Biomol. Spectrosc. 2025;325:125034. doi: 10.1016/j.saa.2024.125034.</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
